Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Increased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC increased its stake in Verve Therapeutics, Inc. (NASDAQ:VERV) by 8.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 262,393 shares of the company’s stock after acquiring an additional 19,925 shares during the period. Los Angeles Capital Management LLC’s holdings in Verve Therapeutics were worth $1,270,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Susquehanna Fundamental Investments LLC acquired a new position in Verve Therapeutics during the first quarter worth about $191,000. ProShare Advisors LLC grew its stake in shares of Verve Therapeutics by 31.0% in the 1st quarter. ProShare Advisors LLC now owns 17,696 shares of the company’s stock worth $235,000 after purchasing an additional 4,184 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Verve Therapeutics by 15.7% in the 1st quarter. Vanguard Group Inc. now owns 6,331,312 shares of the company’s stock worth $84,080,000 after purchasing an additional 859,382 shares in the last quarter. American International Group Inc. lifted its stake in Verve Therapeutics by 25.1% during the first quarter. American International Group Inc. now owns 32,468 shares of the company’s stock valued at $431,000 after purchasing an additional 6,517 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Verve Therapeutics by 28.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 25,366 shares of the company’s stock worth $337,000 after buying an additional 5,600 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Trading Down 7.1 %

NASDAQ:VERV opened at $5.38 on Friday. The business’s fifty day moving average price is $5.47 and its 200 day moving average price is $5.68. The firm has a market capitalization of $455.47 million, a price-to-earnings ratio of -2.19 and a beta of 1.75. Verve Therapeutics, Inc. has a 1-year low of $4.30 and a 1-year high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.11. The company had revenue of $6.87 million for the quarter, compared to analysts’ expectations of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business’s revenue for the quarter was up 120.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.72) EPS. Equities analysts forecast that Verve Therapeutics, Inc. will post -2.53 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Canaccord Genuity Group upped their target price on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Royal Bank of Canada reduced their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, HC Wainwright decreased their target price on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.